

# Non-Invasive Prenatal Testing as a First-Line Screen and Invasive Testing as the Gold Standard: Toward Precision in Prenatal Care

Qamre Alam<sup>1</sup>, Mohamed Ali Ateyah<sup>2</sup>, Mohamed Hani Ali<sup>3</sup>, Kadhem Alkhenazi<sup>4</sup>, Muhammad Umair<sup>5\*</sup>

<sup>1,2,3,4</sup> Department of Molecular Genomics and Precision Medicine, EXPRESSMED Diagnostics and Research, Zinj, Bahrain

<sup>5</sup>Department of Medical Genomics Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs (MNGH), Riyadh, Saudi Arabia.

<sup>5</sup>Department of Life Sciences, School of Science, University of Management and Technology (UMT), Lahore, Pakistan.

Advances in molecular diagnostics have dramatically reshaped prenatal medicine. Non-Invasive Prenatal Testing (NIPT) has emerged as a landmark innovation in the early detection of chromosomal aneuploidies. By analyzing cell-free fetal DNA (cffDNA) circulating in maternal blood, NIPT provides a safe, reliable, and early method of screening, offering families valuable insights during the first trimester.

NIPT has demonstrated remarkable effectiveness in detecting the most common aneuploidies, including trisomy 21 (Down syndrome), trisomy 13 (Patau syndrome) and trisomy 18 (Edwards syndrome). Its sensitivity and specificity far exceed those of conventional screening methods. However, it is critical to emphasize that NIPT is a screening tool rather than a diagnostic test; a high-risk result does not represent a definitive diagnosis and requires confirmation with invasive prenatal diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis, which remain the gold standard.<sup>1</sup>

The rapid global adoption of NIPT can be attributed to its multiple advantages:

- **Safety:** NIPT requires only a maternal blood sample, avoiding the miscarriage risk associated with invasive procedures.
- **Early detection:** Feasible from 10 weeks of gestation, providing families with vital information at the earliest stages of pregnancy.
- **Accuracy:** Demonstrates superior specificity and sensitivity compared to conventional screening.
- **Reduced invasive testing:** Low-risk results and spare families from unnecessary invasive procedures.
- **Fetal sex determination:** Highly accurate in the first trimester, which supports clinical management of different disorders.<sup>2</sup>

Importantly, NIPT and invasive testing should be regarded as complementary, not competing, modalities. NIPT offers a safe and accurate first-line screen for the majority of pregnancies, while invasive testing provides diagnostic certainty when NIPT indicates high risk. Together, this integrated approach minimizes maternal anxiety, reduces unnecessary procedures, and enhances prenatal care outcomes.<sup>3</sup>

## Significance for Pakistan's Healthcare Landscape

In Pakistan, where the burden of genetic disorders is high due to a large population, high consanguinity, and limited access to advanced diagnostic tools, the introduction and implementation of NIPT could have profound clinical and social impact. NIPT would

\*Department of Medical Genomics Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs (MNGH), Riyadh, Saudi Arabia.

<sup>3</sup>Department of Life Sciences, School of Science, University of Management and Technology (UMT), Lahore, Pakistan.

Email: [umairmu@ngha.med.sa](mailto:umairmu@ngha.med.sa)

DOI: <https://doi.org/10.35787/jimdc.v14i3.1456>

enable earlier and safer detection of chromosomal abnormalities. Support clinicians in genetic counseling, pregnancy management and help in shaping public health strategies aimed at reducing the burden of genetic and congenital disorders.

Integrating NIPT into routine obstetric practice in Pakistan requires awareness among healthcare providers, infrastructure development, cost reduction strategies, and supportive government policies. Collaborative efforts between clinicians, geneticists, scientists and policymakers will be essential to ensure equitable access and maximize its benefits for maternal and child health.

#### **Significance for Bahrain's Healthcare Landscape**

Integrating NIPT into Bahrain's healthcare system marks a vital step toward precision reproductive medicine. As awareness of hereditary conditions grows, NIPT provides families with reliable, early-stage risk assessment that guides clinical management and reproductive planning. Extensive experience from thousands of NIPT analyses conducted at Express Med Diagnostics underscores the effectiveness of NIPT within Bahrain's population. By generating robust local evidence, NIPT supports the development of tailored prenatal care pathways, ultimately improving maternal and fetal outcomes, which also aligns with Bahrain's healthcare priorities.<sup>3</sup>

#### **Conclusions and Future Perspectives**

The introduction of NIPT represents a paradigm

shift in prenatal care, empowering families with earlier and safer access to essential genetic information. Looking forward, the scope of NIPT is expected to expand beyond common aneuploidies to include microdeletions, single-gene disorders, and even whole-genome fetal analysis, revolutionizing prenatal medicine.<sup>4</sup>

For Pakistan, the priority should be to establish cost-effective, locally validated NIPT platforms and to integrate them within national healthcare frameworks. Education, training, seminars, workshops, societies and genetic counseling services must accompany testing to ensure appropriate interpretation and use of results.

In summary, the future of prenatal care lies in a balanced integration of NIPT and invasive diagnostics. NIPT as a first-line, safe, and highly accurate screening tool, followed by invasive confirmation when indicated, offers the most effective pathway to delivering optimal prenatal care, reducing the burden of genetic disease, and improving outcomes for families worldwide.

**Acknowledgment:** I would like to express my sincere gratitude to the Molecular Genomics and Precision Medicine Department, EXPRESSMED Diagnostics and Research, Bahrain, and the entire team, especially Sara Jaffer and Jannat, for their continuous support and assistance throughout this work

## References

1. Alyafee Y, Al Tuwaijri A, Alam Q, Umair M, Haddad S, Alharbi M, et al. Next Generation Sequencing Based Non-invasive Prenatal Testing (NIPT): First Report from Saudi Arabia. *Front. Genet.* 2021, 12, 630787. <https://doi.org/10.3389/fgene.2021.630787>
2. Umair M, Rafeeq M, Alam Q, editors. Rare genetic disorders: advancements in diagnosis and treatment. 1st ed. Singapore: Springer; 2024. <https://doi.org/10.1007/978-981-99-9323-9>
3. Alam Q, Rafeeq M, Umair M, editors. Innovations and implications in molecular diagnostics. 1st ed. Boca Raton (FL): CRC Press; 2025. <https://doi.org/10.1201/9781003489177>